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a  b  s  t  r  a  c  t
After  brieﬂy  reviewing  the  nature  of  DNA  methylation,  its general  role  in cancer and  the tools  available
to  interrogate  it, we  consider  the literature  surrounding  DNA methylation  as  relating  to  prostate  cancer.
Speciﬁc  consideration  is given  to recurrent  alterations.  A  list  of  frequently  reported  genes  is  synthesized
from  17 studies  that have  reported  on  methylation  changes  in malignant  prostate  tissue,  and  we chart  the
timing  of those  changes  in the  diseases  history  through  amalgamation  of several  previously  published
data  sets.
We  also  review  associations  with  genetic  alterations  and  hormone  signalling,  before  the  practicalities
of  investigating  prostate  cancer  methylation  using  cell  lines  are  assessed.  We  conclude  by outlining  the
interplay  between  DNA  methylation  and  prostate  cancer  metabolism  and  their  regulation  by  androgen
receptor,  with  a speciﬁc  discussion  of  the  mitochondria  and  their  associations  with  DNA  methylation.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction: why  consider the epigenome?
1.1. The origins of prostate cancer are not obviously genomic
Cancer genomics studies have identiﬁed recurrently mutated
genes and mutation hotspots in a number of cancer types. How-
ever, such studies in prostate adenocarcinomas have identiﬁed no
genes recurrently mutated in more than a seventh of cases [1].
Studies of locally advanced and metastatic prostate cancer have
revealed extensive intratumoural clonal heterogeneity [2–6], in
some cases revealing clones with distinct genomic origins [3,5].
This extensive clonal and spatial heterogeneity creates a signiﬁ-
cant sampling problem for studies that rely on the use of single
tumour specimens. In such studies, intratumoural heterogeneity
will amplify intertumoural heterogeneity, contributing to the low
recurrence rates of genes affected by point mutations in prostate
cancer [1].
Other mutation types have higher levels of recurrence, e.g.
8p deletions (in 40% of cases) and TMPRSS2-ERG fusions (in 50%
of cases) [7,8], suggesting that these may  be early or conver-
gent events in prostate tumourigenesis. However, many prostate
tumours have no deﬁnitive genomic driver event [1]. This is con-
sistent with the existence of events that precede the ﬁrst somatic
point mutations and possibly also the acquisition of the ﬁrst
copy number and structural variants. Epigenomic changes are
among the candidates for early events. Of these, DNA methyla-
tion changes have been widely studied and found to be the most
recurrent events in both locally advanced and metastatic prostate
tumours [9,10].
In prostate cancer, recurrent genome-wide and locus speciﬁc
DNA methylation alterations have been known for decades [11,12]
and these events impact on gene expression potential [12,13]. The
high recurrence rates of speciﬁc somatic alterations in DNA meth-
ylation support a strong selective pressure for these events and
implicate them in the development of neoplastic phenotypes and
as rate limiting steps in disease evolution [12,13]. Cytosine methyl-
ation is the most widely studied epigenetic marker in cancer due to
the development of quantitative genomics methods that are com-
patible with tissue samples obtained from surgical specimens. To
date most studies have used prostate cancer cell lines when pro-
ﬁling chromatin structures and histone modiﬁcations [14–16] and
other variants of cytosine modiﬁcation have only been assessed at a
global level in primary prostate cancer tissue [17]. Therefore for the
purposes of this review we will restrict our focus to the wealth of
studies that have proﬁled cytosine methylation in prostate cancer.
1.2. Considerations for DNA methylation proﬁling in prostate
cancer
DNA methylation is a stable, heritable genome modiﬁcation that
can provide insights into a tumour’s origins and evolution. Methyl-
ation proﬁling is aided by the number of well-developed techniques
and analysis methods available. It is aided also by the requirement
only for standard preparation of genomic DNA as input, making it
applicable to routine tumour tissue collections (i.e. in contrast to
methods that require cross-linked chromatin).
A range of methylation proﬁling methods have been developed,
from cis-linked, base-pair resolution bisulﬁte sequencing of the
whole genome (WGBS [18]) or GC-base enriched regions (eRRBS
[19,20]), to array based averaging of methylation at speciﬁc CpG
sites [21,22], to locus-averaging methods that identify methylation
‘peaks’ (me-DIP [23,24]) or that may  be a proxy for functional meth-
ylation changes (e.g. MBD  pull-down [25,26]). The most widely
used platform for studies of clinical tissue samples is the Inﬁnium
450k array [21], that continues to be used due to its reproducibil-
ity, well developed analysis methods and consequent potential for
integration with a wealth of published data from this platform
[27,28].
Sequencing methods provide the highest resolution proﬁles and
cis-linkage information about the status of adjacent CpGs on the
same strand, but have the largest analytical burden. Standard bisul-
ﬁte sequencing methods do not, however, discriminate between
methyl-cytosine (5-mC) and hydroxy-methyl-cytosine (5-hmC),
although these marks are believed to have different functional con-
sequences. To discriminate 5-hmC and 5-mC a two stage analysis is
required comparing the results of bisulﬁte sequencing (for a com-
bined 5-hmC and 5-mC signal) and oxidative bisulﬁte sequencing
(for 5-hmC alone), followed by subtractive analysis. Alternatively,
me-DIP approaches using 5-hmC and 5-mC speciﬁc antibodies can
also discriminate these signals to provide locus-averaged signals.
Future improvements in sequencing yields and sensitivities for sin-
gle molecule sequencing platforms may  provide different insights
into the epigenetic landscape, for example long read technologies
may  allow better phasing of epigenetic states along chromosome
domains. Recent reports suggest that nanopore-based sequencing
technologies may  be able directly to read the 5-mc or 5-hmc mod-
iﬁcations of cytosine [29].
The DNA methylation landscape varies across the genome,
generally showing higher methylation at repeat sequences and
retrotransposons compared to lower methylation at active gene
promoters and CpG-islands [18,30]. High levels of DNA methyla-
tion at gene promoter regions (and around the transcription start
site) correlates with low gene expression [12,18]. Within a gene
locus the methylation proﬁle can vary widely (Fig. 1A), mean-
ing that comparisons between samples (i.e. differential analysis)
must rely on either comparisons of individual CpG sites or by
deﬁning local methylation domains (e.g. differentially methylated
regions, DMRs) [31]. CpG-islands have low DNA methylation vari-
ance in cancer, while adjacent regions (termed CpG-shelves and
CpG-shores; Fig. 1B) tend to show higher variation. Most recently
locally disordered methylation or epipolymorphisms have been
reported [32,33] and linked to evolutionary plasticity in cancer, as
previously suggested for epigenetic variation [33–35].
The selection of samples for cancer genome sequencing is usu-
ally simple because the aim is to identify somatically acquired
changes (e.g. comparing tumour tissue with a germline control
sample – often blood or buccal swabs). However, tissue spe-
ciﬁc methylation proﬁles mean that the most appropriate control
sample for cancer methylome studies is normal tissue from the
same organ. More stringently, one might aim to match the pro-
portions of cell types (e.g. epithelial, stromal, immune) in the
tumour and normal tissue samples. In many cancer types (includ-
ing prostate cancer) a ‘ﬁeld-effect’ change has been observed in the
tumour adjacent normal tissue, consistent with a pre-neoplastic
state. Therefore, depending on the study aims it may  be most
appropriate to compare epigenetic state between tumours, tumour
adjacent normal tissue and age-matched tumour-free normal
tissue.
1.3. The data used in this review
Through this review we will illustrate key points using previ-
ously published data sets. For ease of comparison, and due to their
greater number, we will focus solely on data generated using the
Illumina Inﬁnium HumanMethylation450 BeadChip. For individual
genes, and to relate methylation levels to gene expression we  will
use the ‘TCGA’ prostate adenocarcinoma data [28], interrogated and
plotted using the TCGA Wanderer interface [36]. For consistency
we use Wanderer’s associations of probes to genes through-
out, although this naturally leads to probes mapping to multiple
genes.
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Fig. 1. (A) Average methylation proﬁles for prostate tumours (n = 340) and normal prostate tissue (n = 49) at the GSTP1 gene locus using the TCGA data set (see Section 1.3).
(B)  Schematic showing the GSTP1 gene locus, indicating the location of the CpG-island, CpG-shore (<2kb from island) and CpG-shelf (2–4kb from island). (C) Correlation
scatter  plot for GSTP1 expression and methylation (using the 450k array probe highlighted in panel-A). (D) Correlation scatter plot for CDKN2A expression and methylation
(using  the 450k array probe highlighted in panel-E). (E) Average methylation proﬁles for prostate at the CDKN2A gene locus using the Prostate TCGA data set (see Section 1.3).
(F)  Schematic showing the gene and CPGI features at the CDKN2A locus.
For the second data set, the ‘Tissue’ data set, we amalgamate
data from several sources [26,27,37–39] to obtain methylation
statuses for prostates from men  with no prostate cancer (“Nor-
mal”), morphologically normal tissue from men  with prostate
cancer (“Benign”), benign prostatic hyperplasia (“Hyperplasia”),
neoplastic tissue (“Neoplasia”), primary tumours (“Tumour”) and
metastases (“Metastasis”). We  also obtain blood proﬁles [39] as an
additional reference.
For Fig. 3A, where space is a constraint, we  use only a subset
of these drawn from two  sources [26,37]. The third data set, the
‘Cell line’ data set consists of the combined HumanMethylation450
data detailed later in Table 1. Finally, to annotate genes with
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 C
.E.
 M
assie,
 et
 al.,
 Th
e
 im
p
ortan
ce
 of
 D
N
A
 m
eth
ylation
 in
 p
rostate
 can
cer
 d
evelop
m
en
t,
 J.
 Steroid
B
ioch
em
.
 M
ol.
 B
iol.
 (2016),
 h
ttp
://d
x.d
oi.org/10.1016/j.jsbm
b.2016.04.009
A
RTICLE IN PRESS
G
 M
odel
SB
M
B
-4702;
 
N
o.
 of
 Pages
 15
4
 
C.E.
 M
assie
 et
 al.
 /
 Journal
 of
 Steroid
 Biochem
istry
 &
 M
olecular
 Biology
 xxx
 (2016)
 xxx–xxx
Table 1
Public prostate cell line methylation data (January 2016).
GoldenGate 27k 450k Nimblegen MBD-seq RRBS NOMe-seq MRE-seq MEDIP
DU-145 GSM1125684,
GSM696035
GSM573668 GSM1633638,
GSM1323599
SRX118022, SRX118022,
GSM1050087,
GSM1050090,
GSM1050093,
GSM1050096,
GSM1050099
GSM1050102
PC3  GSM1125685,
GSM696036
GSM573670 GSM1633598,
GSM1519011 to
GSM1519016*,
GSM1323600
GSM1142996 to
GSM1143004
GSM1050088,
GSM1050091,
GSM1050094,
GSM1050097,
GSM1050100
GSM1050103 GSM1383852
LNCaP  GSM1125683,
GSM696034
GSM573669 (FGC) GSM1519017,
GSM1519018,
GSM999368,
GSM847569 to
GSM847571
GSM1142987 to
GSM1142995*
SRX118021, GSM605080,
GSM605081
GSM683768,
GSM683776,
GSM683862,
GSM683863,
GSM683924,
GSM683946
GSM684592,
GSM684597 to
GSM684600
GSM605948,
GSM605950,
GSM605954 to
GSM605956
ARCaP  GSE35246 (27
samples*)
PrEC GSE35246 (4
samples*)
GSM999369,
GSM847572 to
GSM847574
GSM1142978 to
GSM1142986*
GSM605082, GSM605083 GSM683760,
GSM683838
GSM1383851 GSM684593 to
GSM684596
GSM605945 to
GSM605947,
GSM605951 to
GSM605953
PrED  SRX118020
RWPE-1 GSM573671 GSM1323601
Detailing the data available for common prostate cell lines from Gene Express Omnibus (GSM/GSE) and the Short Read Archive (SRX). * – includes control and treated cell lines. Platforms included include Illumina Goldengate
Methylation Cancer Panel I (“GoldenGate”), Illumina Inﬁnium HumanMethylation27 BeadChip (“27k”), Illumina Inﬁnium HumanMethylation450 BeadChip (“450k”), Nimblegen Human DNA Methylation 3x720K CpG Island Plus
RefSeq  promoter array (“Nimblegen”), methyl-CpG binding domain protein-enriched genome sequencing (“MBD-seq”), Reduced representation Bisulﬁte sequencing (“RRBS”), Nucleosome Occupancy and Methylome sequencing
(“NOMe-seq”), Methylation-sensitive Restriction Enzyme Sequencing (“MRE-seq”), and Methylated DNA Immunoprecipitation Sequencing (“MEDIP”).
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androgen receptor (AR) regulation data, we use two previously-
published androgen-treated cell line time-course data sets [40,39].
2. Recurrent epigenetic changes in prostate cancer:
markers and drivers of disease evolution
Recurrent alterations in DNA methylation at the GSTP1 gene
promoter and concomitant loss of GSTP1 expression in prostate
tumours were reported over 20 years ago [12]. This ﬁnding has
been replicated in countless independent studies (for example
[9,41,42]) and well over 1000 samples (reviewed in [43]), providing
strong evidence that DNA methylation changes are indeed recur-
rent across patient cohorts and could be useful markers for the
clinical detection of prostate cancer [9,44].
Several other genes have also been reported to be recur-
rently hypermethylated in prostate cancer by multiple studies.
Synthesizing data from 17 studies [2,10,20,22,24,26–28,38,45–52],
we identify 861 genes that are reported in two or more stud-
ies, 168 in three or more (detailed in Supplementary Table 1
and Supplementary Fig. 1), and 45 that are reported in four or
more studies (Fig. 2). Some gene families are also recurrently
affected, consistent with functional convergence, including multi-
ple changes at the HOX gene family loci (Fig. 2 and Supplementary
Fig. 1) [10,49].
2.1. Early epigenetic changes in prostate carcinogenesis
The high recurrence rates of these DNA methylation changes
suggest that they may  be early events in tumourigenesis. Indeed
several studies have detected many such methylation changes in
neoplastic samples (PIN) and tumour adjacent, morphologically
benign tissue [53,54,27]. Indeed the majority of loci that have been
suggested as differentiating benign and cancerous prostate appear
already to have undergone epigenetic changes in neoplastic tissue
(Fig. 2) impacting on their potential as prostate cancer markers, but
highlighting early or shared events in cancer evolution.
Prospective multi-region sampling studies with good clinical
annotations are therefore needed to map  tumour speciﬁc mark-
ers comprehensively, in order to improve diagnostic accuracy from
tissue biopsies and non-invasive monitoring. Given the current
over-treatment of primary prostate cancer it is also imperative that
robust panels of markers are developed to allow patient stratiﬁca-
tion for active surveillance or clinical intervention.
2.2. An epigenetic ‘ﬁeld-effect’ in cancerous prostates
Recent studies suggest that DNA methylation changes in tumour
adjacent ‘normal’ tissue may  reﬂect a ‘ﬁeld effect’ in cancerous
prostates [50,24,27]. DNA methylation proﬁles have been reported
to differ between tumour adjacent benign tissue and benign tis-
sue from cancer-free prostates [50,24], while benign samples taken
at different distances from prostate tumours show similar proﬁles,
supporting a wide clonal expansion of morphologically normal cells
[50].
This observation is consistent with the outgrowth of tumour
clones originating from clonal benign and PIN tissue, a concept
supported by a recent study comparing multiple benign, neopla-
sia and tumour samples from the same cancerous prostates [27]. In
this study a common phylogenetic ‘trunk’ could be identiﬁed using
either copy number or DNA methylation proﬁles, linking tumour
samples, PIN and adjacent normal prostate samples. This indication
of a shared clonal ancestry contrasts with the more sparse data from
genome sequencing studies, where few point mutations, indels or
structural variants link separate tumour foci and pre-cancerous
tissues [5], suggesting that the expansion of genetically mutated
clones is a later event than the expansion of clones harbouring DNA
methylation alterations.
Further studies are required to deﬁne more clearly the early
neoplastic and tumour initiating events and also comprehensively
to distinguish early events from convergent evolution. Longitudi-
nal monitoring through the life-history of a patient with prostate
cancer would be required to give a deﬁnitive answer to these
questions, although this would be very difﬁcult to achieve. An alter-
native approach would be to combine multi-region tissue sampling
cohorts with base-pair resolution methylation sequencing to dis-
tinguish early events from convergent evolution. Understanding
this would impact on the utility of these changes both as markers
of early tumourigenesis and as targets for preventative medicine.
2.3. Underlying clonal stability and ongoing epigenetic evolution
in prostate tumours
GSTP1 methylation is present at all stages of prostate can-
cer development [51], showing that speciﬁc epigenetic changes
can be maintained throughout disease evolution. In addition,
methylome-wide studies have shown stable epigenetic proﬁles
between metastatic deposits within a patient [26] and clear evi-
dence of shared origins for metastatic deposits in primary tumours
and premalignant lesions [27]. Interestingly, in most cases neo-
plastic lesions (PIN) were evolutionarily more similar to localized
tumour samples, whereas metastatic deposits were often more
closely related to a separate subset of localized tumour samples
[27].
Hypomethylation of repeat sequences and cancer testes anti-
gens have been suggested to be relatively late events in prostate
cancer development [55,30]. In addition, metastatic sites have been
reported to show greater divergence for DNA hypomethylation
within some patients [30].
Studies showing clonal stability of DNA hypermethylation, and
evidence of a subset of clones that are more closely related to
metastatic disease, support the idea of using DNA  methylation
markers for prostate cancer detection and prognosis.
2.4. DNA methylation markers for the detection and stratiﬁcation
of prostate cancer
Combined panels of candidate DNA methylation markers have
been shown to have high sensitivity and speciﬁcity for the discrim-
ination of prostate cancers from benign tissue [51,38], with more
recent studies showing proof of principle in prostate biopsy mate-
rial [38]. Several studies have shown the potential for non-invasive
monitoring of DNA methylation in cell-free DNA to detect prostate
cancer [56–59]. Many of these studies show remarkable sensitivity
and support the use of these tests for monitoring disease pro-
gression, however larger studies will be required to determine the
clinical utility of these promising tests for prostate cancer diagnosis.
A molecular stratiﬁcation for prostate cancer was  proposed
recently [28]. This large study found associations between genomic
alterations and epigenetic proﬁles, that may  represent a phenotypic
difference between these molecular subtypes of prostate cancer.
One third of ERG-positive tumours clustered together with a dis-
tinct hypermethylation proﬁle [28]. The one percent of prostate
cancers that harbour mutations in the gene encoding isocitrate
dehydrogenase (IDH1) were found to have a divergent genome-
wide hypermethylation proﬁle [28]. This is likely to be a result of
IDH1-R132H mutations driving production of the oncometabolite
2-hydroxyglutarate (2HG), with a reciprocal decrease in alpha-
ketoglutarate, a key component in the metabolic pathways of DNA
methylation (the upstream metabolic processes are described in
Section 3). It is currently unclear whether these molecular subtypes
have clinical utility, what other factors impact on the observed
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cg11603759 PHOX2A cg24530250
cg19513834 POU3F3 cg19513834
cg18459489 VAX1 cg25527090
cg04482110 TMEM106A cg21211480
cg26104932 CYP27A1 cg26104932
cg19456540 SIX6 cg19456540
cg09813610 IRX1 cg10530883
cg06747432 CCDC8 cg06747432
cg15110353 LBX1 cg12646649
cg19183743 HOXA3 cg16644023
cg13570101 NKX2−5 cg13570101
cg07345734 NKX2−1 cg08315174
cg04676771 BARHL2 cg15979173
cg21932416 HOXD8 cg09238180
cg27175287 FOXE3 cg01281911
cg13473120 LHX2 cg14425564
cg06483432 KIT cg27154163
cg00487187 HHEX cg10299976
cg04149039 EN2 cg23426473
cg25243775 FBLN1 cg08149253
cg18750960 HOXD4 cg18750960
cg03916909 NKX2−2 cg03916909
cg18179931 GP5 cg10398774
cg01830294 WNT2 cg20064455
cg05189570 BDNF cg03167496
cg00517511 TBX3 cg19713038
cg24228707 DLX1 cg07181565
cg22389949 ESR1 cg08161546
cg17606785 EFS cg18844382
cg08857479 HOXC11 cg03132556
cg17227967 LAMP5 cg17227967
cg24842086 TBX15 cg13080379
cg06661450 LHX9 cg13364881
cg22153728 RUNX3 cg11018723
cg15607292 RARB cg24396624
cg22953017 AOX1 cg13875120
cg03234186 ZNF154 cg05661282
cg18536802 APC cg22035501
cg12840719 CDKN2A cg12840719
cg25820279 HOXD3 cg14666564
cg10180406 PTGS2 cg26564040
cg18258224 WT1 cg13641903
cg05244766 GSTP1 cg06928838
Fig. 2. Heatmap summary of genes and marker probes associated with DMRs reported in four or more studies. Left panel, correlations between gene expression (RNA-seq)
and  DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs indicated on the left). Middle panel, average methylation levels (Beta-values) from multiple
studies spanning a range of prostate tissue types (450k probes indicated on the right). Right panel, androgen-stimulated gene expression changes in two prostate cancer cell
lines  (autocorrelation values denote a change with time following stimulation – a value of zero indicates no systematic change after stimulation). Missing data are indicated
with  a cross where not obvious.
methylation proﬁles, or what the phenotypic consequences of these
epigenetic differences might be.
More effective diagnosis of prostate cancer would alleviate some
of the current burden on health systems and decrease invasive
procedures on healthy men. However, it is also critically impor-
tant to distinguish indolent from aggressive prostate cancers so
that aggressive treatments can be appropriately allocated to those
patients who require such interventions, sparing other patients
unnecessary over-treatment. Associations between DNA methyl-
ation changes and prognosis have been reported, including the
correlation of PTGS2 (COX-2), HOXD3 and ABHD9 hypermethylation
with recurrence [51,22].
One study aiming to identify prognostic methylation mark-
ers for prostate cancer highlighted over one hundred candidate
genomic loci [49]. However, the discrimination between relapsed
and non-relapsed samples was far weaker than between tumour
and benign samples [49], indicating more subtle differences
between these groups. Among the candidate prognostic markers
only PTGS2 (COX-2) was validated from the previously mentioned
studies. However, other studies have reported more promising
ﬁndings by combining pilot genome-wide screening with targeted
approaches on large test and validation cohorts [60]. A three gene
methylation signature (AOX1, C1ORF114,  HAPLN3) was able to pre-
dict biochemical recurrence with respective hazard ratios of 1.9 and
2.3 in test and independent validation cohorts [60].
By taking a different approach and examining morphologically
normal tissue adjacent to tumours, the methylation status of GSTP1
and APC has been reported to have prognostic utility [61]. GSTP1
and APC methylation in tumour adjacent tissue correlated with the
methylation of these loci in matched tumour samples [61], consis-
tent with either shared clonal ancestry or convergent evolution.
Either hypothesis to explain these DNA methylation changes in
tumour adjacent tissue would support a ﬁeld-effect in a subset of
prostate cancers that may  impact on outcome. These results are
consistent with other reports of an epigenetic ﬁeld effect (sum-
marized in Section 2.2) and conﬁrm other reports that epigenetic
proﬁling could be a useful tool to avoid false-negatives in diagnostic
biopsies [62].
In addition to these important targeted studies in large cohorts
there is a need for methylation proﬁling studies that implement
sensitive, genome-wide methods across samples representing the
full range of prostate cancer disease stages to provide a clearer pic-
ture of the likely diagnostic and prognostic utility of these and other
DNA methylation markers for prostate cancer.
2.5. Epigenetic regulation of alternative promoter usage in
prostate cancer
In addition to gene silencing, DNA methylation can modulate
gene isoform expression by impacting on alternative promoter
regions. For example DNA methylation at the RASSF1,  APC and
NDRG2 loci were shown to result in differential isoform expres-
sion [46]. This isoform selective expression was actively enforced
by the epigenetic status at these loci, as shown by reversal of the
isoform expression proﬁle upon treatment with the demethylat-
ing agent 5-aza-cytidine [46]. Similar events have been reported in
other studies in prostate cancer [63], however the true extent of
this feature will only be made clear by large cohort studies com-
bining comprehensive methylation proﬁling with RNA-sequencing
on the same samples. An exemplar study leveraged the large RNA-
sequencing gene expression data sets generated by TCGA groups
to identify isoform switching in multiple tumour types (includ-
ing prostate cancer), and speculate that epigenetic factors could be
responsible [64]. In this study, tumour samples could be accurately
identiﬁed solely by isoform switching signatures, highlighting the
potential for isoform switching as a marker for prostate cancer.
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2.6. Associations between epigenetic and genetic alterations in
prostate cancer
Given the early and recurrent acquisition of GSTP1 hypermeth-
ylation in prostate tumourigenesis many studies have suggested a
role for GSTP1 silencing in driving disease evolution by increasing
the mutation rate [65–68]. Recent studies integrating methylation
proﬁling with genome sequencing have uncovered additional asso-
ciations between the epigenetic and genetic changes in prostate
cancer.
Firstly, it has been shown that the methylation levels in matched
benign samples are increased at mutated CpG sites in the tumour
in comparison to non-mutated CpGs. [20]. This is consistent with
the hypothesis that methylated cytosines are deaminated to uricil
(and subsequently copied as thymine), a process believed to drive
the observed high C-to-T mutation rates observed in prostate and
other cancer types [69,5].
More surprisingly, it has been reported that sites of tandem
duplication events in prostate cancer are frequently hypomethy-
lated, while interchromosomal translocation break points are
frequently hypermethylated [20]. These intriguing observations
will need to be investigated in larger cohorts with paired methy-
lome sequencing and genome sequencing to better characterize
these associations.
Several studies have also suggested a link between ETS gene
fusion status and DNA methylation proﬁles [46,45,48,28]. LINE
repeats show differential methylation between ERG-positive and
ERG-negative prostate tumours [46], differentially methylated
regions associated with ERG status have been identiﬁed [48] and
alternative mechanisms for EZH2 activation have been proposed in
ERG-negative tumours to phenocopy at least some of the conse-
quences of ETS gene fusions [45]. The implications of molecular
subtype differences in DNA methylation proﬁles are signiﬁcant.
Differences between ETS-fusion positive and negative cases high-
light the interplay between epigeneic state, gene rearrangements
and hormone signalling, since the AR regulates ETS-fusions and AR
signalling is altered in ETS-positive tumours [15]. Equally, these
effects could lead to misinterpretation of studies that cannot take
them into account.
2.7. Epigenetic changes impacting on hormone signalling in
prostate cancer
In addition to interactions with genomic events, the epigenetic
proﬁle has been linked to AR signalling, both as a modulator of
hormone response and a driver event in progression to Castra-
tion Resistant Prostate Cancer (CRPC). AR-bound enhancers were
observed to show greater intratumoural DNA methylation varia-
tion than other enhancer sites [27], suggesting clonal plasticity in
the AR regulome.
An integrative analysis of copy number and DNA methylation
in CRPC revealed convergence on the androgen synthesis path-
way, with copy number and methylation changes converging on
HSD17B2 and other targets that may  be involved in hormone ther-
apy resistance [10].
Loss of AR protein expression is a characteristic of hormone-
relapsed prostate cancer (PCa) that is no longer dependant on AR
signalling, a phenotype that is becoming more common following
the clinical use of second generation AR targeting therapies [70,71].
Epigenetic silencing of AR gene expression has been reported in
prostate tumour samples [72,73] and treatment of AR negative PCa
cells with the global demethylating agent 5-aza-deoxycytadine can
induce functional AR signalling in these cells [73–76]. However,
other studies in CRPC have reported no change in AR promoter
methylation [10], suggesting either differences between analysis
methods or possibly patient cohorts treated with different hor-
mone therapies.
Combining androgen signalling blockade with the demethy-
lating agent 5-aza-deoxycytadine increased response in the
preclinical models of PCa [77,75], suggesting that future studies
combining demethylating agents with second generation AR block-
ade may  improve patient outcome or delay relapse by targeting the
AR, its target genes or upstream pathways.
Oestrogen receptor alpha and beta methylation have also been
identiﬁed in some studies of prostate cancer samples [78,51,46,26].
Although these methylation changes at ER genes are not high-
lighted in the majority of studies it is noteworthy that studies
reporting ER gene methylation used MSP  [51], MBD-pulldown [26]
or restriction enzyme based methods [46] (consistent with either
limitations of the more commonly used 450k arrays at these loci
or convergent artefacts between the other methods). Future stud-
ies should aim to assay DNA methylation at the ERS1 and ESR2
loci in prostate tissues to determine whether this could affect
the interplay between nuclear hormone receptors and be another
mechanism through which epigenetic changes impact on hormone
signalling in prostate cancer.
A large number of these putative epigenetic markers were iden-
tiﬁed by methylation proﬁling of prostate cancer cell lines. In
addition these cell line models are the most widely used tools
for functional validation studies of candidate gene silencing or de-
repression events identiﬁed from genome-wide proﬁling studies.
Therefore we  summarize the utility and limitations of these models
below.
2.8. Prostate cancer cell lines
It has for some time been recognized that immortalized cell
lines do not, in respect of their methylation patterns, reﬂect the
cells from which they originate; typically immortalized cells exhibit
hypermethylation of CpG islands [79–81] although it has been
noted that this may  represent selection pressure where highly
methylated cells are more likely to be immortalized successfully
[82] and there are suggestions that the methylation changes can
predate immortalization [83].
The characteristic methylation changes that occur in immortal-
ized cells are similar to the changes seen in cancers [84,85] raising
the hope that the epigenetics of cancer cell lines may  represent
malignant tissue well. Recent reports argue that it is speciﬁcally the
immortalization of cells rather than other oncogenic activity that
leads to changes in methylation proﬁle [86]. Intriguingly, sites that
are methylated in cancer cell lines are enriched for NANOG binding
sites [87]. As well as its role in maintaining stem cell pluripotency,
NANOG has been shown to be pro-tumourigenic in prostate cancer
cell lines, conferring cancer-stem-cell-like properties [88], and is
directly androgen regulated [89].
Early targeted studies identiﬁed good agreement between
primary cancers and cell lines [90,91], but broader differences
may  mean that only a minority of tumours are well-represented
by cell lines. Genome-wide proﬁling has revealed xenografts to
be a better model in head-and-neck squamous cell carcinomas
[92], while a recent paper has reported near-complete loss of 5-
hydroxymethylcytosine [93] – raising questions about cell lines’
value in this regard.
The utility of prostate cell lines is further affected by the fact
that the commonly used prostate cancer cell line models (recently
reviewed elsewhere [94]) were derived from metastases, and
metastasis itself is associated with changes in methylation proﬁles
[95,96]. Nevertheless, substantial public data exist for a number of
prostate cell lines as denoted in Table 1, notably LNCaP, PC3 DU-145
and PrEC, making them an attractive resource.
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Fig. 3. Cell lines as a representation of primary tumours. (A) Clustering of our exam-
ple  cell line and tissue data sets (described in Section 1.3). The distance between
two samples is deﬁned as Cohen’s Kappa measure of agreement (applied after
dichotomizing methylation beta values). (B) Illustrating, from the cell line and tissue
data sets, the median proportion of methylation at loci near the GSTP1 promoter. As
expected, the cancer cell lines are generally hypermethylated in this region, as are
the neoplastic and malignant tissues. (C) Illustrating, from the cell line and tissue
data  sets, the median proportion of methylation at loci near the TERT gene. An area
in  the gene promoter shows progressively increased methylation levels, with the
cancer cell lines’ levels most in keeping with metastases.
In Fig. 3A, we cluster the available Illumina Inﬁnium Human-
Methylation450 BeadChip cell line data with our example Tissue
data set. It is notable that inter-sample heterogeneity increases
as one progresses through normal, benign, tumour and metasta-
sis samples. Reﬂecting their origins, the prostate cancer cell lines
are more alike the metastasis samples than they are the primary
tumour samples, while the PrEC cells cluster with the normal sam-
ples.
It should be noted that all of the cell lines show levels of agree-
ment with primary tumours that are substantially above chance,
and that their greater similarity to metastases only requires care
to be taken over the interpretation of any results arising. The cell
lines still reﬂect the behaviour of primary tumours at key loci such
as GSTP1 (Fig. 3B), although at loci such as the promoter of TERT
there appears to be progressively greater DNA  methylation as one
moves from normal tissue, through hyperplastic and neoplastic tis-
sues to primary tumours and metastases, the malignant cell lines
showing greater values still (Fig. 3C).
Despite the inevitable caveats about the use of cell lines,
they offer natural advantages for the inference of function. They
enable one to run controlled experiments with identical subjects in
each/every arm, and make it possible to measure multiple charac-
teristics (e.g. genome-wide methylation and transcript abundance)
on effectively the same samples. Both of these have been exploited
to address questions of prostate cancer biology.
To understand better the methylation-driven regulation of the
cancer genome, mRNA expression data are the natural orthogonal
data to bring into an integrative analysis. In this manner, the
methylation-regulated nature of key genes and alternative trans-
criptional start site usage have been explored in prostate cancer
[46,97].
A substantial body of work has linked DNA methylation with
other epigenetic marks better to understand gene regulation in
(prostate) cancer. The H3K27me3 mark at promoters is associated
with inactivated genes, while methylation of promoters is similarly
associated with gene repression, but the two mechanisms have
been seen to be neither exclusive nor deterministically linked in
LNCaP [98]. Where the two  mechanisms do coexist, a dual ther-
apy to reinstate expression of tumour suppressor genes becomes a
possibility [99]. Elsewhere it has been shown that a genome-wide
restructuring of nucleosome densities is associated with changes
in DNA methylation of enhancer regions of PCa cell lines [100].
Other studies have sought to explain epigenetic mechanisms
of treatment and resistance to treatment. Epigenetic silencing of
SLFN11 has been associated with resistance to platinum-based
chemotherapies in a number of cell lines including DU-145 and
PC3 [101], an epigenetic mechanism of the preventative agents sul-
foraphane and 3,39-diindolylmethane is elucidated [102], and the
mechanism of Genistein has been shown not to be dependent on
broad methylation changes, but rather histone acetylation [103].
Perhaps most interestingly for our topic, a recent report has
shown that dosing cells with S-adenosylmethionine (SAM) inhibits
invasion [104]; the same group having previously identiﬁed a role
for hypomethylation in the metastasis of prostate cancer [105].
SAM is an important methyl donor for histone, DNA and RNA
methylation, and all general protein lysine and arginine meth-
ylation (as described in Section 3). The demonstration, in vitro
and in vivo, that replenishing the reservoir of methyl donors
can inhibit metastasis (while only increasing the methylation
status of speciﬁc loci rather than reversing the genome-wide
hypomethylation) provides some evidence of a mechanistic role
for the methylation patterns in metastases, highlights the impor-
tance of the available metabolic pool for cancer progression, and
invites consideration of the broader role of SAM in the metabolic
pathways.
3. Effects of the metabolic pool on DNA methylation
The prostate gland is a metabolically specialized organ
responsible for supporting sperm viability. This specialization
is characterized by net secretion of citrate into the seminal
ﬂuid [106]. Whilst a signiﬁcant reduction in the production
of these metabolites has been reported in numerous mag-
netic resonance spectroscopy studies on clinical samples, the
molecular drivers for this down-regulation remain controversial
[107–110]. Of the polyamines normally produced by the prostate
gland, spermine is particularly abundant [111]. Rat models of
castration-induced regression and testosterone-induced regrowth
of the prostate gland have shown that polyamine production is
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Fig. 4. Schematic representation of metabolic pathways that impact on DNA methylation in prostate cancer. The core DNA methylation pathway is represented at the top of
the  schematic, with connected pathways of relevance to prostate cancer shown below. Colour key relates to metadata annotations shown in Fig. 5. Values for each metabolic
step  are compressed into a single summary to simplify the schematic. Metabolic steps are annotated if: androgen regulation in LNCaP or VCaP gives autocorrelation values
>0.5;  there is a mean methylation change between tumour and normal tissue of ±0.2; the correlation of methylation and expression changes is >0.3 or <−0.3 (see Fig. 5 for
details).
tightly regulated by androgens, in part through control over the
expression of key biosynthetic enzymes (ornithinedecarboxy-
lase (ODC), S-adenosylmethionine decarboxylase (AMD1)
and spermidine synthase (SMS); highlighted in Figs. 4 and
5) [112–114]. The methyl donor in this pathway is S-
adenosylmethioninamine (decarboxy-AdoMet), a metabolite
that is directly downstream of the DNA methylation donor S-
adenosylmethionine (SAM, AdoMet). Therefore, alterations in
the ﬂux through either polyamine metabolism or DNA meth-
ylation would be expected to affect the available pools of
methyl-donors, with reciprocal effects on the ﬂux of the other
pathway.
The prostate has one of the highest concentrations of
polyamines of any tissue in the body and the expression of these
enzymes is associated with glandular epithelial cells with sig-
niﬁcant quantities of polyamines secreted into seminal ﬂuids.
Spermine levels in clinical samples have been reported to corre-
late positively with the differentiation status of the tumour and in
preclinical models to promote growth inhibition [115,116].
Polyamine synthesis requires one-carbon metabolism and in
particular methionine metabolism with S-adenosylmethionine
(SAM) which upon decarboxylation acts as the primary amino-
propyl donor for polyamine synthesis (Fig. 4) [117]. Consequently
the fate of methionine and its derivatives may  be inﬂuenced by
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Fig. 5. Heatmap summary of genes in metabolic pathways that impact on DNA methylation (relating to Fig. 4). Left panel, correlations between gene expression (RNA-seq)
and  DNA methylation (450k arrays), from the PRAD TCGA data set (450k probe IDs indicated on the left). Middle panel, average methylation levels (Beta-values) from multiple
studies spanning a range of prostate tissue types (450k probes indicated on the right). Right panel, androgen-stimulated gene expression changes in two prostate cancer cell
lines  (autocorrelation values denote a change with time following stimulation).
changes in the specialized secretory functions of the prostate gland
as cancer emerges, in particular a decline in polyamine biosynthe-
sis and secretion may  enhance the pool of SAM available to support
epigenetic modiﬁcations (metabolic pathway links shown in Fig. 4).
Proving causative associations between rates of polyamine biosyn-
thesis and regulation of the epigenetic state via the availability
of SAM is extremely challenging, since methylation patterns can
be highly locus and cell-type dependent and are supported by a
complex regulatory network downstream of metabolite consump-
tion and upstream of DNA substrates. Furthermore, one-carbon
metabolism consists of a number of additional interconnected
metabolic processes that may  impinge on polyamines and the
epigenome (folate cycle, methionine cycle and glycine/serine
metabolism, Fig. 4).
Prostate cancer is characterized by the activity of transcription
factors, particularly AR but also others such as c-Myc. A natu-
ral question then is how the transcription factors and important
enzymes interact with the metabolome and epigenetic status of
a tumour. As indicated earlier, the synthesis of polyamines and
the expression of the key enzymes required for this and a num-
ber of other metabolic processes upstream of SAM production are
driven by AR and associated with differentiated prostate cancers
(Figs. 4 and 5). Glycine N-methyltransferase (GNMT) is an enzyme
which converts glycine to sarcosine and in the process converts
SAM to S-adenosylhomocysteine (Fig. 4). In cell-lines expression of
the GNMT enzyme is androgen dependent and in tissue samples it
has been shown to be over-expressed in prostate cancers (Figs. 4
and 5) [118,40]. Sarcosine, the product of the reaction catalysed by
GNMT, has also been reported to be elevated and detectable in urine
samples and some studies have associated this with the emergence
of castrate-resistant disease [119,120]. Of the enzymes involved
in one-carbon metabolism GNMT is therefore currently the most
extensively characterized androgen-dependent component of the
pathway. By contrast the expression of enzymes required for ser-
ine metabolism appears in prostate cancer cell-lines to be repressed
by androgens and in other cancer models to be induced by c-Myc
[40,121]. Whilst serine metabolism also impacts on the methionine
cycle, the most direct impact of serine consumption appears to be to
sustain de novo nucleotide biosynthesis in support of elevated rates
of DNA replication and/or transcription and cell proliferation [122].
This in turn is often a feature of cell cycle dysregulation, character-
istic of late-stage, metastatic prostate cancer [123]. Hypothetically
a phasic transition in one-carbon metabolism may  therefore consist
initially of reduced rates of polyamine biosynthesis and enhanced
DNA and histone methylation in localized disease transitioning into
enhanced serine metabolism during metastatic progression. This
would at least be consistent with the observations that DNA hyper-
methylation is an earlier event in prostate tumourigenesis, while
hypomethylation may  occur in later stage disease (as described in
Section 2).
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The DNA methylation status of a subset of genes encoding these
metabolic enzymes increases between normal samples compared
to benign, tumour and metastasis, consistent with early hyper-
methylation changes (Fig. 5). A separate set of enzyme-encoding
genes show hypomethylation in metastatic samples compared to
localized and pre-malignant samples (Fig. 5), again consistent with
genome-wide observations of later stage hypomethylation (Sec-
tion 2). It is of interest that there appears to be exclusivity of
regulation within the metabolism-related genes illustrated here
(Fig. 5), with AR-regulated genes showing little evidence of dif-
ferential methylation, and the strongest differentially methylated
genes not being AR-regulated. This despite the independence of the
data sets from which these characteristics were identiﬁed.
In addition to the potential inﬂuence of upstream enzyme
expression and metabolite pools on DNA methylation, the de-
methylation pathway is intricately linked to central metabolism.
The TCA cycle metabolite alpha-ketoglutarate is required for TET
enzyme activity, the ﬁrst step in cytosine demethylation (Fig. 4).
Therefore, mitochondrial function may  have a profound effect on
both cytosine methylation and the levels of hydroxymethylation in
the genome of a cell.
4. Mitochondrial methylation and prostate cancer
4.1. Importance of mitochondria in PCa
While of general interest in cancer (reviewed, for example by
Wallace [124]), mitochondria are of speciﬁc interest in prostate
cancer beyond the characteristic zinc-inhibition of TCA cycle and AR
regulation of certain metabolites described in the previous section.
Recent ‘pan-cancer’ analyses have identiﬁed many mutations in
mitochondrial DNA, without showing them to be drivers [125,126],
but animal models have demonstrated the functional impact of
mitochondrial genetic mutations on prostate cancer [127] and a
cohort study in humans has identiﬁed associations with prolifera-
tion [3].
The case for DNA methylation changes in the prostate cancer
mitochondria themselves is not as clear cut as that for genetic
changes. Methylation of mitochondrial DNA has been controver-
sial since it was ﬁrst reported [128]. Subsequent papers variously
conﬁrmed this result [129] or reported no such methylation [130].
The discussion has continued since with arguments for and against
based on sequence analysis [131,132], and use of methylation sen-
sitive and insensitive restriction enzymes [133,134]. One aspect of
the argument against the existence of methylation in the mitochon-
dria has been the absence of the actors that facilitate methylation of
nuclear DNA. However, recent years have seen the identiﬁcation of
methyl donors [135], methyltransferases [136,137], and even TET1
present in the mitochondria [138]. This latter observation suppor-
ting reports of 5-hydroxymethylcytosine in the mitochondrial DNA
[136,139]. The history of this topic is reviewed more thoroughly
elsewhere [140].
Recently there have been studies that provide stronger evidence
that epigenetic modiﬁcations of mitochondrial DNA  do indeed
take place. For example, one study identiﬁed methylated bases in
nucleus-free platelets [141], while another used orthogonal and
complementary technologies to proﬁle the mitochondrial methyl-
ation in a wide range of tissue and cell types [142]. Given the unique
behaviour of mitochondria in prostate cancer, if mitochondrial DNA
can be methylated, this is an aspect that may  reward investigation.
4.2. Reciprocal regulation of nuclear methylation and
mitochondria
Apart from direct epigenetic changes to the mtDNA, the
mitochondria have a complex relationship with epigenetic alter-
ations to the nuclear DNA. Of the order of a thousand coding
genes have products that are active in the mitochondria, and
only 13 originate from the mitochondrial DNA. It follows that
any epigenetic regulation of the remaining mitochondrial actors
in the nucleus will likely inﬂuence mitochondrial behaviour. One
study identiﬁed tissue-speciﬁc differentially methylated regions in
mitochondrial-acting nuclear-encoded genes [143] while another
has concluded that epigenetic regulation of mitochondrial-acting
nuclear-encoded genes was higher than other nuclear-encoded
genes [144]. This latter result can be replicated in prostate cancer
using a single tumour sample (Fig. 6A). While this is representa-
tive of the other samples in our example set, with >5000 probes
from regions around the transcription start sites of mitochondrial
actors showing consistent hypomethylation and approximately
400 showing consistent hypermethylation, there is also evidence of
changes in the regulation of these regions with the progression of
disease. Fig. 6B shows a heatmap of the 114 most variable probes
in these regions, and it is apparent that again there are clusters
of probes that variously gain methylation in neoplastic tissue and
continue to do so in tumour and metastases, others with the oppo-
site pattern, and smaller numbers where the changes are primarily
deﬁned by the metastases samples.
DNA polymerase gamma  is responsible for the replication of
mitochondrial DNA and is regulated by the methylation of the POLG
gene [145,146] leading to associations between mtDNA copy num-
ber and POLG methylation levels. Methylation of the PPARGC1A
gene has also been seen to correlate negatively with mtDNA copy
number.
Fig. 6. (A) Reprod. Fig. 4 of Chinnery et al. for a high-cellularity prostate cancer sample. Probes on the Inﬁnium HumanMethylation450 BeadChip that lay within 1000 bases
of  transcription start sites (TSS) were divided between genes listed in MitoCarta and those that are not. (B) A heatmap of median beta methylation values for different tissues
across probes that show most variation in our data.
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While the methylation of some genes can regulate mtDNA copy
number, it has also been shown that mtDNA copy number can reg-
ulate some nuclear genes [144,147]. Furthermore, studies using
cybrids have shown that the mitochondria can affect nuclear meth-
ylation patterns [139,148]. Given the importance of epigenetics
to prostate cancer regulation, and the characteristic behaviour
of mitochondria (and broader metabolic pathways) in the dis-
ease, these associations demand attention in attempts to unravel
prostate cancer biology.
5. Current perspectives and future directions for the role of
epigenomic changes in prostate cancer
It is clear that clonal expansions of cells with stable epigenomic
changes occur in prostate cancer. DNA methylation changes are
the most recurrent events so far identiﬁed in prostate cancer, and
speciﬁc changes may  associate with outcome. The epigenome con-
tinues to evolve throughout the life history of prostate cancer, with
distinct features presenting at different stages and interacting with
speciﬁc genomic changes. It will be crucial to overlay other epi-
genetic changes within the same cohorts of samples to build up a
picture of the epigenetic landscape in prostate cancer. Future stud-
ies are also needed to integrate both genomic and epigenomic data
in large cohorts of samples, to elucidate the interaction between
genomic and epigenetic changes, to provide a more comprehensive
view of the pathways affected in each prostate tumour sample, and
to assess clinical associations with speciﬁc sets of changes.
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